Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE)
Persistent Cardiovascular Effects of COVID-19 Viral Infection Trial (PERCEIVE): A Randomised Controlled Trial of the Role of Optimal Cardioprotection Strategies to Prevent Heart Failure
Baker Heart and Diabetes Institute
820 participants
Nov 18, 2021
INTERVENTIONAL
Conditions
Summary
This is a prospective study in which a process of identifying and improving a reduction of functional capacity in COVID-19 survivors \>50 years old. The overall goal of this study to identify the feasibility and value of risk-guided medical therapy and exercise intervention in COVID-19 survivors.
Eligibility
Inclusion Criteria2
- History of COVID-19 infection
- Live within a geographically accessible area for follow-up
Exclusion Criteria8
- Valvular stenosis or regurgitation of \>moderate severity
- History of previous heart failure (baseline New York Heart Association (NYHA) classification \>2)
- Inability to acquire interpretable images (identified from baseline echo)
- Contraindications to beta blockers or angiotensin-converting enzyme inhibitors
- Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
- Already taking both angiotensin converting enzyme inhibitors/ angiotensin receptor blockers and beta blockers, or intolerance (or allergy) to both.
- Mobility impairment that would impact participants' ability to perform exercise
- Unable to provide written informed consent to participate in this study
Interventions
A clinical review to ensure optimal risk factor control and cardioprotection along with exercise intervention.
This will be provided by participants' usual healthcare professional(s).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04983823